This case-report evaluates the effectiveness of the medical treatment on vitreomacular
traction through the use of
palmitoylethanolamide (PEA), orally administered. Our 69 year-old patient reported a significant eyesight reduction,
metamorphopsia and
photopsia. He underwent the following investigations, before and after medical treatment: visual acuity evaluation, dilated fundus examination, OCT. The treatment consisted of the administration of two
tablets of PEA per day over 7 days. We observed that, while the visual acuity in the right eye was 2/10 compared to the initial 11/10, the dilated fundus examination highlighted a foveal hole. Moreover, the OCT confirmed the presence of a vitreomacular
traction due to the incomplete
posterior vitreous detachment. At the end of the treatment with PEA, the visual acuity was equal to 8/10 and the OCT showed a disappearance of the hyperreflective streak with recovery of the physiological
retinal and foveal profile. The
therapy was eventually carried on for 10 more days with a final visual acuity of 10/10. In conclusion, PEA orally administered, beyond a rare possibility of a spontaneous resolution of the vitreomacular
traction, probably contributed, by anti inflammatory action, to the vitreolysis and thus to the disappearance of the vitreomacular
traction and foveal hole with a subsequent recovery of the eyesight and of the
metamorphopsia.